Home
>
US Stocks
>
Biohaven Pharmaceutical Holding Company Ltd
Biohaven Pharmaceutical Holding Company Ltd
BHVN

Biohaven Pharmaceutical Holding Company Ltd

$133.626.53%

1D

1W

1M

1Y

3Y

5Y

Key Stats

Open
134.51
Today Low/High
133.14 / 135.07
52 Week Low/High
$57.7 / $132.91
P/E ratio
-8.7748
Market Cap
$7.8B

Company Details

Biohaven Pharmaceutical Holding Company Ltd. is a commercial-stage biopharmaceutical company with a portfolio of innovative, best-in-class therapies to improve the lives of patients with debilitating neurological and neuropsychiatric diseases, including rare disorders. Biohaven's neuroinnovation portfolio includes FDA-approved NURTEC ODT (rimegepant) for the acute treatment of migraine and a broad pipeline of late-stage product candidates across three distinct mechanistic platforms: CGRP receptor antagonism for the acute and preventive treatment of migraine; glutamate modulation for obsessive-compulsive disorder, Alzheimer's disease, and spinocerebellar ataxia; and MPO inhibition for multiple system atrophy and amyotrophic lateral sclerosis.
Organisation
Biohaven Pharmaceutical Holding Company Ltd
Headquaters
New Haven, Connecticut, US
Employees
825
Industry
Health Technology
CEO
Vlad Coric

Discover more

Frequently Asked Questions

What is Biohaven Pharmaceutical Holding Company Ltd share price today

Can Indians buy Biohaven Pharmaceutical Holding Company Ltd shares?

How can I buy Biohaven Pharmaceutical Holding Company Ltd shares from India?

Can Fractional shares of Biohaven Pharmaceutical Holding Company Ltd be purchased?

What are the documents required to start investing in Biohaven Pharmaceutical Holding Company Ltd stocks?

We are a SEBI registered investement advisor